Almirall Förvaltning
Förvaltning kriterier kontrolleras 2/4
Vi har för närvarande inte tillräcklig information om VD:n.
Viktig information
Carlos Gallardo Piqué
Verkställande direktör
n/a
Total ersättning
| VD-lön i procent | n/a |
| Anställning som VD | 4.4yrs |
| Ägande av VD | n/a |
| Ledningens genomsnittliga anställningstid | 4.4yrs |
| Styrelsens genomsnittliga mandatperiod | 5.8yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Feb 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.Uppdatering av berättelse • Jan 19
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.Uppdatering av berättelse • Jan 05
ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.Uppdatering av berättelse • Dec 17
ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Analysartikel • Dec 08
Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...Uppdatering av berättelse • Dec 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.Uppdatering av berättelse • Nov 19
ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Analysartikel • Nov 17
Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Analysartikel • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Analysartikel • Aug 19
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Ny berättelse • Jul 22
European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Analysartikel • May 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Analysartikel • Mar 27
Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Analysartikel • Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...Analysartikel • Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analysartikel • Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Analysartikel • Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Analysartikel • Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Analysartikel • Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analysartikel • Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysartikel • Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...Analysartikel • Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...VD OCH KONCERNCHEF
Carlos Gallardo Piqué (54 yo)
4.4yrs
Anställning
€50,000
Kompensation
Mr. Carlos Gallardo Piqué served as President at Almirall S. A. since January 2024 until May 2026. He has been Chairman of Board at Almirall, S.A. since May 06, 2022. He serves as Chief Executive Officer a...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, Member of Management Board & Chairman of the Board | 4.4yrs | €50.00k | inga uppgifter | |
| CFO & Member of Management Board | less than a year | inga uppgifter | inga uppgifter | |
| Chief Industrial Operations Officer & Member of Management Board | no data | inga uppgifter | inga uppgifter | |
| Chief People & Culture Officer and Member of Management Board | no data | inga uppgifter | inga uppgifter | |
| Chief Medical Officer & Member of Management Board | 6.4yrs | inga uppgifter | inga uppgifter | |
| Chief Scientific Officer & Member of Management Board | 5.4yrs | inga uppgifter | inga uppgifter | |
| Company Vice Secretary | 4.4yrs | inga uppgifter | inga uppgifter | |
| Member of Management Board and President & GM of Almirall US | 1.7yrs | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer of Europe & International and Member of Management Board | less than a year | inga uppgifter | inga uppgifter | |
| Senior Director of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Acting CSO and Head of R&D | no data | inga uppgifter | inga uppgifter | |
| Company Secretary | 4.4yrs | inga uppgifter | inga uppgifter |
4.4yrs
Genomsnittlig anställningstid
Erfaren ledning: ALM s ledningsgrupp anses vara erfaren ( 4.4 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, Member of Management Board & Chairman of the Board | 11.9yrs | €50.00k | inga uppgifter | |
| Member of Global Advisory Board-Spain | 17.4yrs | inga uppgifter | inga uppgifter | |
| Vice-Chair & Lead Independent Director | 7.3yrs | inga uppgifter | inga uppgifter | |
| Director | less than a year | inga uppgifter | inga uppgifter | |
| Independent Director | 5.8yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 5yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 2.1yrs | inga uppgifter | inga uppgifter | |
| Proprietary Director | 11.9yrs | €50.00k | inga uppgifter | |
| External Independent Director | 10.1yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 5.8yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 2.1yrs | inga uppgifter | inga uppgifter |
5.8yrs
Genomsnittlig anställningstid
66yo
Genomsnittlig ålder
Erfaren styrelse: ALM s styrelse anses vara erfaren ( 5.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/10 05:09 |
| Aktiekurs vid dagens slut | 2026/06/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Almirall, S.A. bevakas av 27 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |